Drug Approval | December 27, 2022
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
None of the observations are related to data integrity and management believes that they are addressable
The product is backed by required scientific proof and comparative bioequivalence studies
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
These satellite institutes will further strengthen the research, international collaborations and facilitate affordable Ayush services for the larger community.
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
